中山醫學大學機構典藏 CSMUIR:Item 310902500/23875
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 17938/22957 (78%)
造访人次 : 7396110      在线人数 : 171
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.csmu.edu.tw:8080/ir/handle/310902500/23875


    题名: Cessation of Nucleos(t)ide Analogue Therapy in Non-Cirrhotic Hepatitis B Patients with Prior Severe Acute Exacerbation
    作者: Lai, CY;Yang, SS;Lee, SW;Tsai, HJ;Lee, TY
    关键词: hepatitis flare;liver failure;hepatitis B virus;antivirals;discontinuation
    日期: 2021
    上传时间: 2022-08-05T09:44:17Z (UTC)
    出版者: MDPI
    摘要: Chronic hepatitis B (CHB) with severe acute exacerbation (SAE) is an urgent problem requiring nucleos(t)ide analogue (NA) therapy. We aim to evaluate the clinical relapse (CR) risk after discontinuing NA in patients with prior SAE. Methods: In this retrospective cohort study, CHB patients who discontinued NA therapy were screened between October, 2003 and January, 2019. A total of 78 non-cirrhotic patients who had received NA therapy for CHB with SAE, i.e., bilirubin & GE; 2 mg/dL and/or prothrombin time prolongation & GE;3 s, (SAE group) were matched 1:2 with 156 controls without SAE (non-SAE group) by means of propensity scores (age, gender, NA categories, NA therapy duration, and HBeAg status). Results: The 5-year cumulative incidences of severe CR, i.e., ALT > 10X ULN, (42.78%, 95% CI: 27.84-57.73% vs. 25.42%, 95% CI: 16.26-34.58%; p = 0.045) and SAE recurrence (25.91%, 95% CI: 10.91-40.91% vs. 1.04%, 95% CI: 0-3.07%; p < 0.001) were significantly higher in the SAE group. Prior SAE history (HR 1.79, 95% CI: 1.04-3.06) was an independent factor for severe CR. The 5-year cumulative incidence of HBsAg seroclearance was significantly higher in the SAE group than that in the non-SAE group (16.82%, 95% CI: 2.34-31.30% vs. 6.02%, 95% CI: 0-13.23%; p = 0.049). Conclusions: Even though it creates a greater chance of HBsAg seroclearance, NA therapy cessation may result in a high risk of severe CR in non-cirrhotic CHB patients with prior SAE.
    URI: http://dx.doi.org/10.3390/jcm10214883
    https://www.webofscience.com/wos/woscc/full-record/WOS:000721219100001
    https://ir.csmu.edu.tw:8080/handle/310902500/23875
    關聯: JOURNAL OF CLINICAL MEDICINE ,2021,v10,issue 21
    显示于类别:[中山醫學大學研究成果] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    index.html0KbHTML195检视/开启


    SFX Query

    在CSMUIR中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈